Physician barriers to population-based, fecal occult blood test-based colorectal cancer screening programs for average-risk patients

S Elizabeth McGregor PhD1, Robert J Hilsden MD PhD2, Huiming Yang MD3

BACKGROUND: Colorectal cancer (CRC) screening is an efficacious but underused means to reduce the burden of CRC. Population-based CRC screening programs are currently being implemented in Canada and physicians are key partners in increasing screening uptake. The current study identified physician attitudes and barriers that need to be addressed by provincial programs.

METHODS: A mailed survey of primary care physicians in Alberta. The survey response rate was 42.4% (806 of 1903). The majority of physicians suggested CRC screening as part of a routine periodic examination; however, the approach to test selection and the type of tests recommended varied by geographical region. The majority of physicians agreed (48%) or strongly agreed (36%) that a province-wide screening program is the best approach to reducing mortality from CRC. However, there were many serious concerns identified – the most common was endoscopic capacity for follow-up of patients with a positive fecal occult blood test (FOBT), which was cited by 55% to 69% of the physicians surveyed. The barriers to three commonly available tests (FOBT, flexible sigmoidoscopy and colonoscopy) varied according to health region, and the types of barriers identified varied according to the specific test.

INTERPRETATION: Screening for CRC is gradually being accepted among primary care physicians in Alberta. A key finding of the present descriptive study was the regional variation in practices, perceived barriers and concerns about provincial population-based screening programs based on FOBT as the primary screening test. Provincial programs will need to address the issue of endoscopic capacity and perceived barriers to FOBT to gain primary care physician acceptance of FOBT-based CRC screening programs.

Key Words: Colorectal cancer; Health surveys; Mass screening; Primary care

Colorectal cancer (CRC) is an important public health problem and the second leading cause of death from cancer among Canadians, with an estimated 22,000 cases and approximately 9100 deaths expected in Canada in 2009 (1). Although there is strong evidence that screening can reduce the incidence of and mortality from CRC, screening rates remain low (2-5). Indeed, CRC screening has been identified as a high-impact, cost-effective, underused service (6) that merits strong consideration for incorporation into medical practice (7).

Over the past decade, organizations that provide evidence-based recommendations to physicians (8-10) and professional societies (11,12) have consistently recommended CRC screening for individuals who are at average risk. The Canadian Task Force on Preventive Health Care released guidelines in 2001 (10), which recommended for the first time that average-risk Canadians should be screened for CRC. The fecal occult blood test (FOBT) was recommended based on evidence from four large randomized trials and a meta-analysis, which indicated...
that annual or biennial FOBT screening was efficacious in reducing CRC mortality from 15% to 33%. The Canadian Association of Gastroenterology (13) recommended the establishment of CRC screening programs, with choices for testing determined by patient preference, current evidence and local resources. More recently, the province of Alberta issued a clinical practice guideline (14) that recommends options for testing, including annual FOBTs.

A government of Canada committee recommended the implementation of FOBT-based screening programs in 2002 (15). To date, at least four provinces in Canada (Ontario, Manitoba, Alberta and Nova Scotia) have announced plans to implement population-based CRC screening programs with the FOBT as the primary screening test offered to asymptomatic, average-risk adults 50 years of age and older.

Physicians are key partners in population-based screening programs (16) because physician recommendation is a strong predictor of acceptance of CRC screening (17-19). Canadian physicians have been encouraged to screen patients for CRC since 2001 (10,20,21). High provider adherence to CRC screening guidelines is a critical assumption in models supporting the cost effectiveness of CRC screening (22).

The purpose of the present survey was to determine attitudes toward CRC screening among primary care physicians in Alberta to identify key issues that need to be addressed in the implementation of province-wide screening; to compare attitudes and barriers according to health region; to assess their response to the newly announced, province-wide screening program; and to compare changes in attitudes and barriers since 2002, when a similar survey was conducted.

METHODS

Data were collected from January through May 2008 using a mailed survey. The entire target population comprised all licensed primary care physicians in active clinical practice in Alberta for whom CRC screening was relevant. A random sample of primary care physicians from each of three geographical areas, defined by regional health authority boundaries in place in December 2007, was selected from a database of currently licensed physicians that was purchased from the College of Physicians and Surgeons of Alberta. The three geographical regions were the Calgary Health Region (CHR, population 1.3 million), the Capital Health Region (Capital, population 1.1 million) and the remainder of the province (nonmetropolitan health regions, population 1.1 million). The total sample size was 2191.

The structured questionnaire, a booklet consisting of 26 questions, ascertained information on current approaches to CRC screening, demographic and practice characteristics, opinions regarding CRC screening and perceived barriers to FOBT, flexible sigmoidoscopy and colonoscopy as screening tests for CRC. Definitions of average risk, defined as a person without a condition (eg, ulcerative colitis or Crohn’s disease) that would predispose them to the development of CRC, and screening FOBTs were provided. A short description of the plans to implement a province-wide CRC screening program over the next five years with annual FOBT as the primary screening test was provided.

The study package – including a cover letter, a reply card physicians could return to indicate why they would not be completing the survey, the questionnaire and a self-addressed, postage-paid envelope – was mailed to all physicians selected for the study. An incentive (a draw for one of 10 $150 gift certificates at a retail chain of bookstores) was offered to physicians who returned a completed survey. Two follow-up mailings, consisting of a complete study package with a different cover letter for each follow-up mailing, were sent to nonresponders. The survey was pilot tested using a sample of 30 primary care physicians.

The usual screening practices, barriers to potential screening tests and opinions regarding CRC screening are described. The percentages were weighted for the three geographical health regions sampled. χ² tests were used to test for differences according to geographical region. Region-specific estimates are presented if significant regional variation was present (based on P<0.05).

The study was approved by the Conjoint Health Research Ethics Board of the University of Calgary (Calgary, Alberta) and the Research Ethics Board of the Alberta Cancer Board.

RESULTS

The response rate was 42.4% (806 of 1903) after excluding those who were unreachable (n=45 of 2191 [2.1%]), retired/deceased (n=61 of 2191 [2.8%]) or for whom the topic was not relevant (n=182 [8.3%]).

Comparison of respondents and nonrespondents showed that respondents were representative of Alberta nonspecialist physicians with respect to geographical region, sex and College of Family Physicians certification (data not shown). The characteristics of physicians who completed the survey are presented in Table 1.

Usual approach to CRC screening

There was considerable regional variation in the usual approach to CRC screening for average-risk patients (Table 2). The majority of physicians suggested that CRC screening should be a part of the examination; however, the approach to test selection and the type of tests recommended varied according to geographical region. CHR physicians were most likely to offer options for testing, while physicians from other regions were more likely to recommend a specific test. The most common options for testing were FOBTs and colonoscopy, with more than 96% of physicians including FOBT as an option. Among physicians who recommended a specific test, FOBT was most commonly recommended; however, 39% of physicians in the CHR recommended colonoscopy as the primary screening test.

The majority of respondents (78.6%) indicated that there was a need for print resources in their practice to help educate patients and their families about CRC screening. Many physicians would refer patients who wanted more information about CRC screening to a Web site (89.2%), a ‘1-800’ telephone number (61.0%) or a nurse-led educational session (61.8%), if they were available.

Potential concerns regarding provincial screening programs

The majority of physicians agreed (48%) or strongly agreed (36%) that a province-wide screening program is the best approach to reducing mortality from CRC. However, there were a number of serious concerns identified, the most common being endoscopic capacity for follow-up of patients with a positive FOBT, followed by patients’ general lack of awareness...
Health care resource barriers were the most common barriers for the structural examinations (flexible sigmoidoscopy and colonoscopy) and were highest for colonoscopy (Table 5). Almost all physicians indicated at least one resource barrier for colonoscopy, with long wait times being the most common barrier. The percentage of barriers cited by physicians varied according to geographical region. Fewer physicians practicing in nonmetropolitan geographical regions reported barriers than physicians practicing in major urban centres (ie, CHR, Capital).

Comparisons with the previous survey regarding opinions about CRC screening

Table 6 compares responses to the current survey with those from a mailed survey of Alberta primary care physicians that was conducted in 2002 (23) using essentially the same methods. Respondents in the 2002 survey were less likely to be 50 years of age or older (32.1% in 2002 versus 40.1% in 2008), more likely to be male (60.5% in 2002 versus 53.3% in 2008), and less likely to have been in practice for less than five years (13.6% in 2002 versus 17.3% in 2008) or more than 15 years (50.8% in 2002 versus 46.5% in 2008). The majority of physicians in both surveys were in group practice (80.2% in 2002 versus 80.0% in 2008).

Respondents to the 2008 survey were more supportive of CRC screening than respondents to the 2002 survey (Table 6). The majority of respondents to the 2008 survey considered

| TABLE 1 | Characteristics of respondents (n=806) |
|---------|--------------------------------------|
| Age group, years | n* | % (weighted by region) |
| 25–34 | 135 | 16.6 |
| 35–49 | 350 | 43.4 |
| 50–64 | 281 | 34.8 |
| Sex | | |
| Male | 453 | 53.3 |
| Female | 353 | 46.7 |
| University appointment | | |
| Yes | 175 | 21.5 |
| No | 624 | 78.5 |
| Years in practice | | |
| <5 | 138 | 17.3 |
| 5–10 | 116 | 14.5 |
| 11–15 | 118 | 14.3 |
| >15 | 434 | 53.9 |
| Practice setting | | |
| Solo | 90 | 11.3 |
| Group | 649 | 80.0 |
| Other | 60 | 8.7 |
| Use an electronic medical record | | |
| Yes | 540 | 65.8 |
| No | 258 | 34.2 |
| Belong to a primary care network | | |
| Yes | 472 | 61.0 |
| No | 330 | 39.0 |
| Patients per week, mean | 781 | 128 |
| Choice of screening test if they themselves were to be screened for CRC | | |
| None | 9 | 1.1 |
| Colonoscopy | 414 | 51.5 |
| Colonoscopy and FOBT | 62 | 7.8 |
| FOBT | 190 | 23.4 |
| CT colonography | 56 | 6.9 |
| Other, including multiple | 82 | 10.3 |

*Sum differs from 806 due to missing information. CRC Colorectal cancer; CT Computed tomography; FOBT Fecal occult blood test

| TABLE 2 | Usual approach to colorectal cancer (CRC) screening for average-risk patients |
|---------|-------------------------------------------------|
| Usual approach to average-risk patient with no symptoms or concerns about CRC who present for a routine check up* Physicians who selected each approach according to geographical region, % | CHR | Capital | Nonmetro |
| CRC | (n=262) | (n=231) | (n=313) |
| Do not raise issue | 2.1 | 1.4 | 6.0 |
| Discuss, see if patient wants to pursue | 21.6 | 16.9 | 18.5 |
| Suggest screening as part of routine examination | 76.3 | 81.8 | 75.6 |
| Usual approach to screening test selection for an average-risk patient* Physicians who selected each approach according to geographical region, % | CHR | Capital | Nonmetro |
| FOBT | 39.0 | 65.2 | 55.0 |
| Flexible sigmoidoscopy | 57.4 | 95.3 | 84.2 |
| Colonoscopy | 38.6 | 1.3 | 11.7 |
| FOB and colonoscopy | 3.0 | 1.3 | 2.3 |
| Recommend several options that include the following tests† (n=364) | 59.8 | 35.7 | 42.1 |
| FOBT | 96.8 | 100.0 | 96.2 |
| FOB and colonoscopy | 25.8 | 46.2 | 37.4 |
| Air-contrast barium enema | 30.3 | 47.4 | 29.8 |
| Colonoscopy | 97.4 | 84.6 | 87.8 |
| Computed tomography colonography (virtual colonoscopy) | 23.9 | 2.6 | 3.8 |

*χ² test for differences according to geographical region (P<0.001); †Most frequently recommended tests. Capital (Capital Health Region); CHR (Calgary Health Region); Nonmetro (Nonmetropolitan health regions)

about CRC screening (Table 3). Concern about FOBTs as the primary screening test was considered to be serious in the CHR but less so in the other two geographical regions.

Reported access to colonoscopy varied considerably according to geographical region, with physicians in the CHR reporting longer wait times for patients referred for all types of colonoscopies (Table 4). Wait times were shortest for physicians practicing in major urban centres (ie, CHR, Capital).

Perceived barriers to potential CRC screening tests

The perceived barriers to three commonly available tests (FOBT, flexible sigmoidoscopy and colonoscopy) are shown in Table 5. Patient-related barriers were common, particularly for colonoscopy. Barriers related to test characteristics were also common but the actual test characteristic differed according to the type of test. The potential to miss cancers was a major barrier for FOBT and less so for flexible sigmoidoscopy. Too many false positives were also a concern for FOBT. The potential for complications was the major barrier to colonoscopy. Lack of efficacy evidence was considered by some physicians to be a barrier to FOBT and flexible sigmoidoscopy, but not to colonoscopy.
TABLE 3
Potential concerns regarding a provincial colorectal cancer screening program with the fecal occult blood test (FOBT) as the primary screening test according to health region

| How much, if at all, do you perceive the following to be a concern? | Serious concern | Moderate concern | No concern |
|---------------------------------------------------------------|----------------|-----------------|-----------|
|                                                              | CHR            | Capital         | Nonmetro  |
| Endoscopic capacity for follow-up of patients with positive FOBTs (n=797) (P<0.001)* | 55.2           | 68.8            | 58.3      |
| Patients’ general lack of awareness and knowledge about colorectal screening (n=796) (P=0.3)* | 31.8           | 25.9            | 31.9      |
| FOBT as the primary screening test (n=789) (P<0.001)*           | 28.2           | 10.5            | 17.5      |
| Time required to discuss colorectal cancer screening with patients (n=796) (P=0.9)* | 17.0           | 17.0            | 16.9      |
| Effective communication about patients between the program and family physicians (n=784) (P=0.9)* | 14.2           | 17.0            | 15.5      |

Data presented as %. *χ² test for differences according to geographical region. Capital (Capital Health Region); CHR (Calgary Health Region); Nonmetro (Nonmetropolitan health regions)

TABLE 4
Reported wait times for patients referred for colonoscopy according to geographical region (% of physicians indicating patients referred for colonoscopy wait a specified time)

| Type of colonoscopy | CHR          | Capital       | Nonmetro          |
|---------------------|--------------|---------------|-------------------|
| Screening*          | <6 weeks     | 9.5           | 14.7              | 34.9          |
|                     | 7–12 weeks   | 27.0          | 45.3              | 40.1          |
|                     | >7 months    | 43.2          | 36.0              | 21.0          |
| For follow-up of a positive fecal occult blood test* | 20.2 | 14.0 | 4.0 |
| <6 weeks            | 4.6          | 6.2           | 25.5              |
| 7–12 weeks          | 21.3         | 26.1          | 31.0              |
| >12 months          | 39.2         | 49.6          | 32.9              |
| >12 months          | 27.5         | 15.9          | 9.4               |
| >12 months          | 7.4          | 2.2           | 1.3               |

*χ² test for differences according to geographical region (P<0.001). Capital (Capital Health Region); CHR (Calgary Health Region); Nonmetro (Nonmetropolitan health regions)

TABLE 5
Perceived potential barriers to three commonly available colorectal cancer screening tests

| Physicians who indicated the following as barriers, % | FOBT | Flexible sigmoidoscopy | Colonoscopy |
|------------------------------------------------------|------|------------------------|-------------|
| Patient acceptance*                                  | 56.7–77.4† | 65.0 | 87.7 |
| Low patient acceptance/ compliance                   | 46.8–67.8† | 45.8 | 55.1 |
| Preparation required by patient                      | 31.7–51.7† | 52.2 | 83.9 |
| Test characteristics*                                | 89.2 | 58.6–70.0† | 59.3–80.0† |
| Potential to miss cancers (false negatives)          | 83.4 | 47.8 | 2.9 |
| Too many false positives                             | 49.4–60.0† | 1.1 | <1 |
| Potential for complications                         | <1  | 24.4–39.6† | 58.3–78.7† |
| Lack of efficacy evidence                            | 27.1 | 13.3 | 1.8 |
| Health care resources*                               | 4.3  | 51.3–69.6† | 91.0–97.3† |
| Cost to health care system                           | <1  | 20.8–33.5† | 64.4–76.5† |
| Availability/ease of access for patients            | 4.2  | 37.8–56.1† | 70.5–80.4† |
| Long wait times                                      | <1  | 32.7–47.4† | 80.8–95.4† |

*At least one of the barriers in this category selected; †Significant regional variation (P<0.05) in the percentage of physicians indicating a barrier – lowest and highest percentages shown, otherwise a single weighted percentage is presented

CRC screening to be cost effective. Although this was an improvement from the 2002 survey, it should be noted that 62% of respondents to the 2008 survey agreed or strongly agreed that inconsistent recommendations make it difficult to decide which tests should be offered to patients. Perceived compliance with recommendations for screening was very similar in the two surveys, with less than one-third of respondents in each survey estimating that at least 75% of their patients actually complete the recommended screening test.

**DISCUSSION**

The findings from the 2008 survey, and comparison with a similar survey in 2002 (23), suggest that screening for CRC is obtaining gradual acceptance among primary care physicians in Alberta. The proportion of primary care physicians who recommend CRC screening has increased; however, patient compliance with screening recommendations is still perceived to be low. Inconsistencies in screening recommendations remain a problem for primary care physicians. A key finding of the present descriptive study was the regional variation in practices, perceived barriers and concerns regarding provincial population-based screening programs based on the FOBT as the primary screening test.

Qualitative and mixed methods studies (24,25) have found that physician perception of patient noncompliance with a recommendation for screening is a barrier to CRC screening. Our findings suggest that educational resources for patients are needed, particularly practice-based print resources and Internet sites that physicians can refer patients to. Education programs for the general public about the importance of CRC screening may also be needed to address physician concerns about the general lack of awareness and knowledge about CRC screening.

The increasing use of colonoscopy as a primary screening test for CRC (26), particularly in light of the 2008 United States...
respectively, between those who offered average-risk screening patients, with total median wait times of 99 days and 66 days, to colonoscopic follow-up of patients with a positive FOBT is necessary to achieve the mortality reductions seen in randomized controlled trials and is an important component of organized population-based screening programs (38). Clearly, screening programs will need to convince physicians that there is adequate capacity for endoscopic follow-up of positive FOBTs if population-based programs based on FOBT are to be widely accepted.

Our study was limited by its cross-sectional design. It is not possible to ascertain the influence of the various clinical practice guidelines, or the announcement of the provincial CRC screening program on physician CRC screening opinions and practices. The data on screening practices are based on self-reports, which may over- or underestimate actual practices (39). Our response rate was similar to those typically attained in large mailed surveys of physicians (40) and of surveys of Canadian physicians regarding other cancer screening tests (41,42). Selection bias remains a possibility, although respondents did not differ from nonrespondents in terms of geographical location of practice, sex and College of Family Physicians of Canada training. A review of physician surveys comparing early versus late responders (a proxy for nonresponders) found few differences in demographic factors, suggesting nonresponse bias may be less important in physician surveys than in surveys of the general public (43).

**CONCLUSION**

Physician attitudes toward CRC screening have improved over the past six years, and the majority of primary care physicians recommend screening for average-risk patients. Concerns regarding FOBT-based provincial screening programs have been identified and barriers exist to all screening methods. Colonoscopy remains the screening test that the majority of

**TABLE 6**

Comparison of opinions and colorectal cancer (CRC) screening practices between the 2002 and 2008 surveys

| Screening practices | Survey year |
|---------------------|-------------|
|                     | 2008 | 2002 |
|---------------------|------|------|
| Recommend average-risk patients be screened | 96   | 75   |
| Start screening at 50 to 59 years of age | 84   | 69   |
| Recommend screening to >75% of patients | 71   | 39   |
| Calgary Health Region | 68   | 36   |
| Capital Health Region | 57   | 32   |
| Estimated percentage of patients who comply with screening recommendations, % |     |
| <25% | 5   | 11  |
| 25% to 49% | 15  | 18  |
| 50% to 74% | 32  | 28  |
| ≥75% | 32  | 28  |
| Do not know | 16  | 15  |
physicians in our study would choose for themselves, and its use as a primary screening test for patients is increasing. Provincial programs will need to address the issue of endoscopic capacity and barriers to FOBT to gain primary care physician adherence to programs based on FOBT as the primary screening test. Public education programs and educational resources for patients may assist in this process. The findings of regional variation in practices and barriers highlight the need for provincial programs to work with communities of physicians to address regional concerns.

REFERENCES
1. Canadian Cancer Society's Steering Committee. Canadian Cancer Statistics 2009. Toronto, Canadian Cancer Society, 2009.
2. Shapiro JA, Stee LC, Thompson TD, Nadel MR, Klubunde CN, Vernon SW. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008;17:1623-30.
3. McGregor SE, Hilsden RJ, Li FX, Bryant HE, Murray A. Colorectal cancer screening: Health impact and cost effectiveness. Am J Prev Med 2006;31:52-61.
4. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
5. McGregor SE, Hilsden RJ, Murray A, Bryant HE. Colorectal cancer screening: Practices and opinions of primary care physicians. Prev Med 2004;39:279-85.
6. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
7. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
8. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
9. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
10. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
11. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
12. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
13. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
14. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
15. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
16. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
17. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
18. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
19. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
20. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
21. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
22. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
23. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
24. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
25. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
26. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
27. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
28. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
29. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
30. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
31. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
32. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
33. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
34. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
35. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
36. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
37. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
38. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
39. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
40. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
41. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
42. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
43. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
44. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
45. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
46. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
47. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
48. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
49. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
50. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
51. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
Submit your manuscripts at http://www.hindawi.com